Heck Capital Advisors LLC Makes New Investment in Thermo Fisher Scientific Inc. (NYSE:TMO)

Heck Capital Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,090 shares of the medical research company's stock, valued at approximately $567,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Barrett & Company Inc. purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth about $28,000. FPC Investment Advisory Inc. bought a new position in Thermo Fisher Scientific in the fourth quarter worth approximately $28,000. Pillar Financial Advisors LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $29,000. Ameriflex Group Inc. bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at about $30,000. Finally, Noble Wealth Management PBC bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at about $35,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Price Performance

Shares of TMO traded down $1.34 during mid-day trading on Friday, hitting $402.41. The company's stock had a trading volume of 2,521,302 shares, compared to its average volume of 1,878,887. The firm has a 50-day moving average price of $430.85 and a 200 day moving average price of $499.77. The stock has a market capitalization of $151.91 billion, a price-to-earnings ratio of 24.34, a PEG ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a fifty-two week low of $390.50 and a fifty-two week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm's revenue was up .2% on a year-over-year basis. During the same period in the previous year, the firm posted $5.11 earnings per share. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's payout ratio is 10.09%.

Wall Street Analysts Forecast Growth

TMO has been the topic of several research reports. Raymond James reaffirmed an "outperform" rating and issued a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Stifel Nicolaus dropped their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a report on Friday, January 31st. UBS Group reduced their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Finally, Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research note on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $607.43.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,075 shares of company stock valued at $7,305,942 in the last ninety days. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.